［1］SUNG H，FERLAY J，SIEGEL RL，et al.Global cancer statistics 2020：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin，2021，71(3)：209-249.
［2］XIA C，DONG X，LI H，et al.Cancer statistics in China and United States，2022：Profiles，trends，and determinants［J］.Chin Med J（Engl)，2022，135(5)：584-590.
［3］AFIFY SM，HASSAN G，SENO A，et al.Cancer-inducing niche：The force of chronic inflammation［J］.Br J Cancer，2022，127(2)：193-201.
［4］BALKWILL F，MANTOVANI A.Inflammation and cancer：Back to virchow［J］.Lancet，2001，357(9255)：539-545.
［5］COLOTTA F，ALLAVENA P，SICA A，et al.Cancer-related inflammation，the seventh hallmark of cancer：Links to genetic instability［J］.Carcinogenesis，2009，30(7)：1073-1081.
［6］HANAHAN D，WEINBERG RA.Hallmarks of cancer：The next generation［J］.Cell，2011，144(5)：646-674.
［7］LIU X，YIN L，SHEN S，et al.Inflammation and cancer：Paradoxical roles in tumorigenesis and implications in immunotherapies［J］.Genes Dis，2023，10(1)：151-164.
［8］CAI J，SUN L，GONZALEZ FJ.Gut microbiota-derived bile acids in intestinal immunity，inflammation，and tumorigenesis［J］.Cell Host Microbe，2022，30(3)：289-300.
［9］TUOMISTO AE，MAKINEN M ，VAYRYNEN JP.Systemic inflammation in colorectal cancer：Underlying factors，effects，and prognostic significance［J］.World J Gastroenterol，2019，25(31)：4383-4404.
［10］CHELA HK，GANGU K，ERTUGRUL H，et al.The 8th wonder of the cancer world：Esophageal cancer and inflammation［J］.Diseases，2022，10(3)：44-60.
［11］YANG YM，KIM SY，SEKI E.Inflammation and liver cancer：Molecular mechanisms and therapeutic targets［J］.Semin Liver Dis，2019，39(1)：26-42.
［12］JAROENLAPNOPPARAT A，BHATIA K，COBAN S.Inflammation and gastric cancer［J］.Diseases，2022，10(3)：35-70.
［13］PADOAN A，PLEBANI M，BASSO D.Inflammation and pancreatic cancer：Focus on metabolism，cytokines，and immunity［J］.Int J Mol Sci，2019，20(3)：676-696.
［14］DAN W，PENG L，YAN B，et al.Human microbiota in esophageal adenocarcinoma：Pathogenesis，diagnosis，prognosis and therapeutic implications［J］.Front Microbiol，2021，12：791274.
［15］ZHANG M，ZHOU S，ZHANG L，et al.Role of cancer-related inflammation in esophageal cancer［J］.Crit Rev Eukaryot Gene Expr，2013，23(1)：27-35.
［16］CHEN Y，WANG D，PENG H，et al.Epigenetically upregulated oncoprotein PLCE1 drives esophageal carcinoma angiogenesis and proliferation via activating the PI-PLCε-NF-κB signaling pathway and VEGF-C/Bcl-2 expression［J］.Mol Cancer，2019，18(1)：1.
［17］ZHAO X，TANG YP，WANG CY，et al.Prognostic values of STAT3 and HIF-1α in esophageal squamous cell carcinoma［J］.Eur Rev Med Pharmacol Sci，2019，23(8)：3351-3357.
［18］HE F，XIAO H，CAI Y，et al.ATF5 and HIF1α cooperatively activate HIF1 signaling pathway in esophageal cancer［J］.Cell Commun Signal，2021，19(1)：53.
［19］TASNEEM S，SARWAR MT，BASHIR MR，et al.Expression analysis of cyclooxygenase-2 in patients suffering from esophageal squamous cell carcinoma［J］.PLoS One，2018，13(10)：e0205508.
［20］WANG C，ZHOU M，ZHU P，et al.IGF2BP2-induced circRUNX1 facilitates the growth and metastasis of esophageal squamous cell carcinoma through miR-449b-5p/FOXP3 axis［J］.J Exp Clin Cancer Res，2022，41(1)：347.
［21］GOTO M，SHIBAHARA Y，BACIU C，et al.Prognostic impact of CXCR7 and CXCL12 expression in patients with esophageal adenocarcinoma［J］.Ann Surg Oncol，2021，28(9)：4943-4951.
［22］ZHAO Q，HUANG L，QIN G，et al.Cancer-associated fibroblasts induce monocytic myeloid-derived suppressor cell generation via IL-6/exosomal miR-21-activated STAT3 signaling to promote cisplatin resistance in esophageal squamous cell carcinoma［J］.Cancer Lett，2021，518：35-48.
［23］YANG K，XIE Y，XUE L，et al.M2 tumor-associated macrophage mediates the maintenance of stemness to promote cisplatin resistance by secreting TGF-β1 in esophageal squamous cell carcinoma［J］.J Transl Med，2023，21(1)：26.
［24］KARIMI P，ISLAMI F，ANANDASABAPATHY S，et al.Gastric cancer：Descriptive epidemiology，risk factors，screening，and prevention［J］.Cancer Epidemiol Biomarkers Prev，2014，23(5)：700-713.
［25］FORD AC，YUAN Y，MOAYYEDI P.Helicobacter pylori eradication therapy to prevent gastric cancer：Systematic review and Meta-analysis［J］.Gut，2020，69(12)：2113-2121.
［26］LI Y，ZHONG X，ZHANG Y，et al.Mesenchymal stem cells in gastric cancer：Vicious but hopeful［J］.Front Oncol，2021，11：617677.
［27］WANG L，CHANG EW，WONG SC，et al.Increased myeloid-derived suppressor cells in gastric cancer correlate with cancer stage and plasma S100A8/A9 proinflammatory proteins［J］.J Immunol，2013，190(2)：794-804.
［28］MA J，LIANG W，QIANG Y，et al.Interleukin-1 receptor antagonist inhibits matastatic potential by down-regulating CXCL12/CXCR4 signaling axis in colorectal cancer［J］.Cell Commun Signal，2021，19(1)：122.
［29］HUANG B，LANG X，LI X.The role of IL-6/JAK2/STAT3 signaling pathway in cancers［J］.Front Oncol，2022，12：1023177.
［30］QU Y，WANG X，BAI S，et al.The effects of TNF-α/TNFR2 in regulatory T cells on the microenvironment and progression of gastric cancer［J］.Int J Cancer，2022，150(8)：1373-1391.
［31］SONG C，ZHOU C.HOXA10 mediates epithelial-mesenchymal transition to promote gastric cancer metastasis partly via modulation of TGFB2/Smad/METTL3 signaling axis［J］.J Exp Clin Cancer Res，2021，40(1)：62.
［32］ZHANG P，GU Y，FANG H，et al.Intratumoral IL-1R1 expression delineates a distinctive molecular subset with therapeutic resistance in patients with gastric cancer［J］.J Immunother Cancer，2022，10(2)：e00407.
［33］XU M，REN L，FAN J，et al.Berberine inhibits gastric cancer development and progression by regulating the JAK2/STAT3 pathway and downregulating IL-6［J］.Life Sci，2022，290：120266.
［34］PORTER RJ，ARENDS MJ，CHURCHHOUSE AMD，et al.Inflammatory bowel disease-associated colorectal cancer：Translational risks from mechanisms to medicines［J］.J Crohns Colitis，2021，15(12)：2131-2141.
［35］NADEEM MS，KUMAR V，AL-ABBASI FA，et al.Risk of colorectal cancer in inflammatory bowel diseases［J］.Semin Cancer Biol，2020，64：51-60.
［36］CUI ML,ZHANG MX,ZHANG C,et al.Tumor-associated inflammation in colon cancer［J］.World Chinese Journal of Digestology，2016，24(32)：4343-4353.
［37］PATEL M，HORGAN PG，MCMILLAN DC，et al.NF-κB pathways in the development and progression of colorectal cancer［J］.Transl Res，2018，197：43-56.
［38］XU K，ZHAN Y，YUAN Z，et al.Hypoxia induces drug resistance in colorectal cancer through the HIF-1α/miR-338-5p/IL-6 feedback loop［J］.Mol Ther，2019，27(10)：1810-1824.
［39］XI X，TENG M，ZHANG L，et al.MicroRNA-204-3p represses colon cancer cells proliferation，migration，and invasion by targeting HMGA2［J］.J Cell Physiol，2020，235(2)：1330-1338.
［40］TENG MW，VESELY MD，DURET H，et al.Opposing roles for IL-23 and IL-12 in maintaining occult cancer in an equilibrium state［J］.Cancer Res，2012，72(16)：3987-3996.